Table 2.
Category | Name | Reference and clinical trials |
---|---|---|
T cell surface | Interleukin-2 receptor alpha chain (CD25) | NCT02922283 (357, 358, 365–367) |
OX40 receptor (CD134) | NCT02318394 (359, 368) | |
T cell receptor (TCR) | (361, 369, 370) | |
CD3 | (351, 371, 372) | |
CD4 | (362) | |
CD8 |
NCT03107663, NCT03802123, NCT03610061 (347, 363, 364) |
|
Metabolic pathways | L-leucine analogue | (373–375) |
18F-FAC | (376–378) | |
18F -CFA | NCT03409419 (377, 379–381) | |
18F-FLT | (382–384) | |
18F-F-AraG |
NCT03311672, NCT03142204, NCT03007719 (385, 386) |
|
18F-FDG | (387–391) | |
Effector function | Granzyme B | (392–395) |
Interferon-gamma | (396) | |
Checkpoint receptors |
NCT03065764, NCT02760225, NCT03313323 (397–399) |